CAR-T Cell Therapy: The Limitation and Solution DOI

S Y Wang

Highlights in Science Engineering and Technology, Journal Year: 2024, Volume and Issue: 102, P. 444 - 450

Published: July 11, 2024

Driven by breakthroughs in biomedical research, chimeric antigen receptor (CAR) T cell therapy has been a potential new class of the that is now being explored field biology with regard to cancer treatment.These genetically engineered immune cells are designed selectively target antigens expressed on tumour cells, presenting novel avenue immunotherapy. Particularly liquid tumours such as acute lymphoblastic leukaemia (ALL), noteworthy therapeutic performance CAR-T highlights their promise treatment research.Nevertheless, despite remarkable achievements, considerable challenges persist. Issues an immunosuppressive microenvironment (TME), loss, and restricted trafficking, especially solid tumours, present formidable obstacles. Researchers have proposed strategies aimed at surmounting these challenges, including dual-targeted design TME modification, which offer promising avenues for advancement. However, unresolved questions linger, emphasizing ongoing need innovative solutions.

Language: Английский

Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers DOI
Kai Zhang,

Yang Mi,

Bohao Zhang

et al.

Oncogene, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells DOI Creative Commons
Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 28, 2024

Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are urgent need additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target other cancers, specifically upregulated cell surface antigen high risk myeloma tumors. We use structure-guided design to define CD27-based anti-CD70 CAR-T that outperforms all tested scFv-based CARs, leading >80-fold improved expansion vivo. Epigenetic analysis via machine learning predicts key transcription factors transcriptional networks driving CD70 upregulation myeloma. Dual-targeting against either or BCMA demonstrate potential strategy avoid escape-mediated resistance. Together, these findings support promise targeting optimized well future clinical translation this approach.

Language: Английский

Citations

4
Tuning CAR T-cell therapies for efficacy and reduced toxicity DOI

Danielle Blud,

Patricia Rubio-Reyes,

Rachel Perret

et al.

Seminars in Hematology, Journal Year: 2024, Volume and Issue: 61(5), P. 333 - 344

Published: July 6, 2024

Language: Английский

Citations

3
Better, Faster, Stronger: Accelerating mRNA‐Based Immunotherapies With Nanocarriers DOI Creative Commons

Henrique Carvalho,

Tiago A. S. Fidalgo,

Rita C. Acúrcio

et al.

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, Journal Year: 2024, Volume and Issue: 16(6)

Published: Nov. 1, 2024

ABSTRACT Messenger ribonucleic acid (mRNA) therapeutics are attracting attention as promising tools in cancer immunotherapy due to their ability leverage the vivo expression of all known protein sequences. Even small amounts mRNA can have a powerful effect on vaccines by promoting synthesis tumor‐specific antigens (TSA) or tumor‐associated (TAA) antigen‐presenting cells (APC). These then presented T cells, eliciting strong antitumor immune stimulation. The potential be further enhanced expressing immunomodulatory agents, such cytokines, antibodies, and chimeric antigen receptors (CAR), enhancing tumor immunity. Recent research also explores mRNA‐encoded death inducers microenvironment (TME) modulators. Despite its promise, clinical translation mRNA‐based anticancer strategies faces challenges, including inefficient targeted delivery vivo, failure endosomal escape, inadequate intracellular release, resulting poor transfection efficiencies. Inspired approval lipid nanoparticle‐loaded against coronavirus disease 2019 (COVID‐19) encouraging outcomes therapies trials, innovative nonviral nanotechnology systems been engineered. aim advance immunotherapies from application. This review summarizes recent preclinical progress polymeric nanomedicines for delivering therapeutics, cytokines antibody‐based immunotherapies, vaccines, CAR therapies. It addresses advanced direct oncolysis TME reprogramming highlights key challenges translating these use, exploring future perspectives, role artificial intelligence machine learning development.

Language: Английский

Citations

1
CAR-T Cell Therapy: The Limitation and Solution DOI

S Y Wang

Highlights in Science Engineering and Technology, Journal Year: 2024, Volume and Issue: 102, P. 444 - 450

Published: July 11, 2024

Driven by breakthroughs in biomedical research, chimeric antigen receptor (CAR) T cell therapy has been a potential new class of the that is now being explored field biology with regard to cancer treatment.These genetically engineered immune cells are designed selectively target antigens expressed on tumour cells, presenting novel avenue immunotherapy. Particularly liquid tumours such as acute lymphoblastic leukaemia (ALL), noteworthy therapeutic performance CAR-T highlights their promise treatment research.Nevertheless, despite remarkable achievements, considerable challenges persist. Issues an immunosuppressive microenvironment (TME), loss, and restricted trafficking, especially solid tumours, present formidable obstacles. Researchers have proposed strategies aimed at surmounting these challenges, including dual-targeted design TME modification, which offer promising avenues for advancement. However, unresolved questions linger, emphasizing ongoing need innovative solutions.

Language: Английский

Citations

0